2026年11月17日 美国东部时间下午6:28 / CBS新闻
特朗普总统提名的FDA(美国食品药品监督管理局)局长人选海蒂·奥弗顿博士,正面临压力,难以在参议院卫生、教育、劳工与养老金委员会筹得足够支持,该委员会将于本周三就她的提名举行投票。
消息人士向CBS新闻透露,她在委员会中难以找到足够共和党议员投票支持推进其提名,若无法获得足够支持,提名可能被撤回。预计委员会中所有民主党议员都不会支持她。
一位消息人士表示,白宫知道自身面临问题,已开始寻找新的候选人。另一位消息人士确认,白宫已在与潜在候选人接触,包括可出任代理局长、因此无需参议院确认的人选。
CBS新闻已联系白宫置评。
奥弗顿的提名陷入停滞,原因在于她在FDA批准的化学堕胎药物米非司酮相关证词,以及她在国内政策委员会任职期间执行特朗普政府的支持 vaping(电子烟)政策的做法。
密苏里州共和党参议员乔希·霍利已成为质疑者之一。奥弗顿回避了有关如何处理特朗普政府长期承诺的米非司酮安全研究的问题,霍利也一直推动开展这项研究。反堕胎组织“苏珊·安东尼”敦促参议院推迟对她的确认,并要求FDA承诺禁止米非司酮的邮寄订单。
委员会中两名支持堕胎选择权的共和党议员——缅因州参议员苏珊·柯林斯和阿拉斯加州参议员丽莎·穆尔科斯基——也尚未表明是否会投票支持推进她的提名。在奥弗顿的提名听证会上,穆尔科斯基询问她是否会限制米非司酮的使用,该药用于美国一半以上的堕胎手术。
白宫已与有意以代理身份出任FDA局长的候选人接洽。这是在当前仅剩三周的立法窗口期内,绕开参议院确认程序的一条途径。FDA监管的产品约占消费者支出的20%。
两名消息人士表示,堪萨斯州的共和党医生参议员罗杰·马歇尔正在争取FDA局长职位,他本月早些时候刚刚输掉了民主党议员亚当·汉密尔顿的连任竞选。
奥弗顿可以说是特朗普提名的人选,在共和党控制国会的最后几周里,她是难以获得足够支持的最受关注的人选。
周二,特朗普提名的海军部长人选洪·曹因管理战时行动,以及五角大楼禁止部分民主党议员参加机密军事简报会的决定,面临两党议员的严厉质询。即将退休的北卡罗来纳州共和党参议员汤姆·蒂尔维斯周二表示,他反对目前担任管理和预算办公室副主任的埃里克·尤兰德担任政府问责局局长的提名,理由是尤兰德和管理与预算办公室在实施DOGE(政府效率部)削减政策方面的参与。
自去年春天参议院确认的前任局长马蒂·马卡里被白宫强迫离职后,FDA一直由代理局长凯尔·戴曼塔斯负责。多名熟悉其离职原因的消息人士告诉CBS新闻,白宫对风味电子烟的持续施压造成了重大摩擦。
马卡里博士在11月8日向CBS新闻发表的声明中表示:“大型烟草公司利用他们与政府和卫生与公众服务部官员的关系,反复向我施压,要求我批准吸引儿童的水果味电子烟——我不会这么做。”
特朗普在2024年竞选期间承诺要拯救 vaping,这一戒烟替代品有助于人们戒烟,但也被发现存在严重健康副作用。
CBS新闻的《与玛格丽特·布伦南共同主持的面对国家》节目询问即将卸任的参议院卫生、教育、劳工与养老金委员会主席、路易斯安那州共和党议员比尔·卡西迪,共和党能否在他们控制参议院的最后几周里任命一名经参议院确认的FDA局长。他提出了一个担忧,即替代方案意味着任命代理局长。
“我们想要一系列短期管理者,他们可能会受到卫生与公众服务部长的更多影响,而不是某个虽可能不是大家心目中的完美人选,但至少是长期的、能够建立一定独立性的人。这是考虑的部分思路。这在权衡利弊的一方,当然其他因素也在另一方权衡,”卡西迪周日表示。
当被《面对国家》节目问及他过去曾称奥弗顿与特朗普减少儿童疫苗接种的努力相关“几乎丧失资格”的言论时,卡西迪承认他仍在打电话沟通,不确定他担任主席的卫生、教育、劳工与养老金委员会是否会推进奥弗顿的提名,他也未表明自己的投票倾向。
今年夏天,奥弗顿在椭圆形办公室与特朗普一同签署疫苗行政命令时,总统两次错误地将麻疹或MMR疫苗称为“致命的”。在场的卫生官员没有纠正特朗普的说法。
近期辞职的“让美国健康再次伟大”(MAHA)组织领袖卡利·米恩斯,曾是卫生与公众服务部部长小罗伯特·F·肯尼迪的高级顾问,也敦促他的追随者帮助阻止奥弗顿的确认。他告诉《面对国家》节目:“海蒂·奥弗顿是我在政府中遇到的对MAHA政策的最大阻碍。”
奥弗顿的支持者驳斥了关于她不符合特朗普政策的批评,并指出她的医学背景以及两名前FDA局长的背书,以此作为她将胜任该职位的迹象。
截至目前,确认奥弗顿以及其他几名卫生官员提名的投票仍定于周三上午进行。
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/headshot-600-ed-okeefe.jpg
Trump FDA nominee Heidi Overton struggling to win enough GOP support to be confirmed
November 17, 2026 / 6:28 PM EST / CBS News
Dr. Heidi Overton, President Trump’s pick to be FDA commissioner, is struggling to shore up enough support in the Senate Health, Education, Labor and Pensions Committee as it prepares to vote on her nomination Wednesday.
Sources tell CBS News that she’s having trouble finding enough Republicans on the committee to vote to advance her nomination, which could be pulled if she can’t muster the support. None of the Democrats on the committee are expected to back her.
The White House knows it has a problem, one source said, and has already begun looking for a new candidate. A second source confirmed that the White House has been talking to potential candidates, including some who could serve in an acting capacity and thus forgo Senate confirmation.
CBS News has reached out to the White House for comment.
Overton’s nomination has run aground over her testimony regarding the FDA-approved chemical abortion drug mifepristone and her execution of President Trump’s pro-vaping policies while she served on the Domestic Policy Council.
Missouri Republican Sen. Josh Hawley has emerged as one of the skeptics. Overton sidestepped questions on how she would handle a safety study long promised by the Trump administration into mifepristone, which Hawley has pressed for as well. The anti-abortion group Susan B. Anthony urged the Senate to delay her confirmation, and wants the FDA to commit to banning mail orders of mifepristone.
And two pro-abortion-access Republicans on the committee — Sens. Susan Collins of Maine and Lisa Murkowski of Alaska —have also not said whether they’ll vote to advance her nomination. During Overton’s confirmation hearing, Murkowski asked her whether she would restrict mifepristone, which is used in more than half of abortions in the U.S.
The administration has spoken with candidates about taking the FDA commissioner role in an acting capacity. That’s one route to avoiding the Senate confirmation process during the narrow three-week legislative window ahead. The FDA oversees products that account for roughly 20% of consumer spending.
Two sources indicated Sen. Roger Marshall of Kansas, a doctor, is making a play for the FDA post. He lost his reelection bid to Democrat Adam Hamilton earlier this month.
Overton is arguably the Trump nominee with the highest profile who is struggling to shore up sufficient support in the closing weeks of GOP congressional control.
On Tuesday, Hung Cao, Mr. Trump’s pick to serve as secretary of the Navy, faced a bipartisan grilling over his management of wartime operations and the Pentagon’s decision to block Democrats from some classified military briefings. And retiring North Carolina Republican Sen. Thom Tillis said Tuesday he opposes the nomination of Eric Ueland, currently the deputy director of the Office of Management and Budget, to lead the Government Accountability Office, because of the involvement of Ueland and OMB in implementing DOGE cuts.
The FDA has been helmed by acting Commissioner Kyle Diamantas since the last Senate-confirmed chief, Marty Makary, was forced out by the White House last spring. Multiple sources familiar with his ouster told CBS News that ongoing White House pressure over flavored vapes caused significant friction.
Dr. Makary told CBS News in a statement on Nov. 8 that “big tobacco exploited their connections to administration and HHS officials to put repeated pressure on me to approve fruit-flavored vapes that appeal to children – I wouldn’t do it.”
Mr. Trump campaigned in 2024 on a promise to save vaping, a smoking alternative that can help with breaking the smoking habit, but also has been found to have serious health side effects.
CBS News’ “Face the Nation with Margaret Brennan” asked outgoing HELP Chairman Sen. Bill Cassidy, Republican of Louisiana, about whether Republicans would be able to install a Senate-confirmed FDA commissioner in these last weeks that they control the Senate. He raised the concern that the alternative would mean installing acting commissioners.
“Do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody’s mind, but at least would be a permanent one and have the ability to establish some independence. And that’s part of the thought process there. That weighs on one side, and of course other things weigh on the other,” Cassidy said Sunday.
Asked by “Face the Nation” about his own past remarks that Overton’s association with Mr. Trump’s efforts around reducing childhood vaccine uptake was “almost disqualifying,” Cassidy acknowledged he was still working the phones and uncertain about whether Overton’s nomination would be advanced by the HELP Committee he chairs, and he also did not say which way he would vote.
Overton stood beside Mr. Trump in the Oval Office as he signed an executive order on vaccines this summer — and the president twice erroneously referred to the measles or MMR vaccine as “lethal.” None of the health officials present corrected Mr. Trump.
Recently resigned MAHA leader Calley Means, a former top adviser to Health and Human Services Secretary Robert F. Kennedy Jr., has also urged his followers to help block Overton’s confirmation. He told “Face the Nation,” “Heidi Overton was the biggest block to MAHA policies I encountered in the government.”
Defenders of Overton dismissed criticism of her compliance with Mr. Trump’s policies, and point to her medical background and her endorsement by two former FDA commissioners as a sign that she will be a professional.
At this hour, the vote to confirm Overton and a handful of other health officials is still scheduled to take place Wednesday morning.
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/headshot-600-ed-okeefe.jpg
发表回复